MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 129046 | Name: HN0037

Description:

WARNING: This product is for research use only, not for human or veterinary use.

HN0037 is a helicase-primase inhibitor.

Chemical Structure

HN0037
HN0037
CAS#2233566-79-3

Theoretical Analysis

MedKoo Cat#: 129046

Name: HN0037

CAS#: 2233566-79-3

Chemical Formula: C20H20N4O3S2

Exact Mass: 428.1000

Molecular Weight: 428.53

Elemental Analysis: C, 56.06; H, 4.70; N, 13.07; O, 11.20; S, 14.96

Price and Availability

Related CAS #
No Data
Synonym
HN-0037; HN 0037; HN0037
IUPAC/Chemical Name
(R)-N-methyl-N-(4-methyl-5-sulfamoylthiazol-2-yl)-5-(pyridin-2-yl)-2,3-dihydro-1H-indene-2-carboxamide
InChi Key
KVGIVOAGCRDHHH-MRXNPFEDSA-N
InChi Code
InChI=1S/C20H20N4O3S2/c1-12-19(29(21,26)27)28-20(23-12)24(2)18(25)16-9-13-6-7-14(10-15(13)11-16)17-5-3-4-8-22-17/h3-8,10,16H,9,11H2,1-2H3,(H2,21,26,27)/t16-/m1/s1
SMILES Code
O=C(N(C1=NC(C)=C(S1)S(N)(=O)=O)C)[C@@H]2CC(C=CC(C3=CC=CC=N3)=C4)=C4C2
Appearance
To be determined
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 -4 C for short term (days to weeks) or -20 C for long term(months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 428.53 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

1: Hou J, Gao H, Fan Y, Wang Y, Qin M, Di Y, Wang L, Zhou X, Zhou Y, Qin D, Hill

G. Pharmacokinetics and Safety Study of HN0037, a Novel Anti-Human Herpes

Simplex Virus Inhibitor, in Healthy Volunteers. Clin Pharmacol Drug Dev. 2022

Dec;11(12):1467-1473. doi: 10.1002/cpdd.1138. Epub 2022 Jul 6. PMID: 35794079.

 

2: Gege C, Kleymann G. Helicase-primase inhibitors from Medshine Discovery Inc.

(WO2018/127207 and WO2020/007355) for the treatment of herpes simplex virus

infections - structure proposal for Phaeno Therapeutics drug candidate HN0037.

Expert Opin Ther Pat. 2022 Sep;32(9):933-937. doi:

10.1080/13543776.2022.2113873. Epub 2022 Aug 19. PMID: 35965439.

 

3: Gege C, Kleymann G. Helicase-primase inhibitors for the treatment of herpes

simplex virus infections - patent evaluation of WO2023/225162 from Gilead

Sciences Inc. Expert Opin Ther Pat. 2024 Oct;34(10):863-872. doi:

10.1080/13543776.2024.2403618. Epub 2024 Sep 17. PMID: 39262042.

 

4: Gege C, Kleymann G. Replacement of sulfonamide by sulfoximine within a

helicase-primase inhibitor with restricted flexibility. Bioorg Med Chem Lett.

2024 Jul 1;106:129761. doi: 10.1016/j.bmcl.2024.129761. Epub 2024 Apr 19. PMID:

38642810.